Aegle Therapeutics
is running a Phase 1/2a trial of AGLE-102, an MSC-derived extracellular-vesicle therapy for dystrophic epidermolysis bullosa, having dosed its first patient and reported positive initial safety data.
- Country
- United States
msc-derived-ev
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Exosome therapy & extracellular vesicles | regenerative-personalized | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.